Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

n-process R&D. In addition, the company restructuring which was announced in November 2008, has led to several adjustments in balance sheet values of assets and liabilities. More information can be found in the Notes to the Financial Statements in the 2008 Annual Report.

Statutory Accounts

Since inception, Arpida has chosen to capitalise research and development costs in its Statutory Accounts. In light of the announced company restructuring and the sharply reduced market capitalisation, this policy was reviewed. It was decided to write down 100% of the capitalised R&D expenses, resulting in an impairment charge in the Statutory Accounts. This does not impact the consolidated accounts, as R&D was never capitalised in these.

Outlook

After completion of the restructuring that was initiated at the end of 2008, the burn rate is expected to fall to around CHF 1 million on average per month from the second quarter of 2009 onwards. Cash and financial investments are expected to be around CHF 17 million at year-end 2009.

Pipeline Development

Intravenous iclaprim in cSSSI - setback in regulatory process

In 2008, regulatory filings for intravenous iclaprim in complicated skin and skin structure infections (cSSSI) were submitted in the USA, the European Union and in Canada.

On 20 November 2008, the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration (FDA) voted 17 to 2 against the approval of intravenous iclaprim for use in the treatment of patients with cSSSI. In January 2009, Arpida received the FDA's Complete Response Letter. The FDA indicated in its letter that they could not approve the application for intravenous iclaprim in its current form and required additional clinical data to demonstrate efficacy in order to gain approval. Arpida has initiated a dialogue with external experts and the FDA to develo
'/>"/>

SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... (PRWEB) May 26, 2015 Innovacyn, ... solutions in the human and animal health industries, ... Vetericyn® Future Innovators of Agriculture College Scholarship Award. ... senior who exhibits a passionate commitment to the ... , This year’s winners, Alexis Pedrow from Anderson ...
(Date:5/26/2015)... , May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: ... president and CEO, will provide an update on the progress ... overview of the company,s business strategy at 1:30pm ET on ... Conference. The conference is being held in New ... webcast live and may be accessed via a link on ...
(Date:5/26/2015)... May 26, 2015 Tianyin Pharmaceutical Inc. (NYSE ... in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... the Company,s Annual Meeting of Shareholders for fiscal year ... held at the Company,s office located in ... 9:00 AM (local time in Chengdu, China ...
(Date:5/26/2015)... N.Y. , May 26, 2015   ... and solutions, today announced that Oakwood Healthcare in ... selected as the winning entry in ... industry professionals who display excellence in building collaborative ... (ES) teams in healthcare facilities.  ...
Breaking Biology Technology:Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... SOUTH EASTON, Mass., Feb. 18 Pressure BioSciences, Inc. (Nasdaq: ... that it has received $1.8 million from the sale of ... February 12, 2009. Each unit was priced at $11.50 ... Convertible Preferred Stock, (ii) a warrant to purchase, at the ...
... trial indicate pre-converted form of Coenzyme Q10 positively ... 18 Results from the first clinical trial ... showed that the newly available pre-converted form of ... critically ill patients. Published in the January ...
... Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: ... December 31, 2008. Net loss for the three month period ... compared with a net loss of $1,049,838 or $0.06 per ... This increase in net loss was primarily the result ...
Cached Biology Technology:Pressure BioSciences, Inc. Announces Completion of Private Placement 2Pressure BioSciences, Inc. Announces Completion of Private Placement 3Pressure BioSciences, Inc. Announces Completion of Private Placement 4KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure 2KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure 3Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 2Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 3Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 4Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 5Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 6Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... available in German . The kea, a New ... the two most intelligent avian families. Researchers from the Department ... problem solving abilities as well as their innovative capacities. They ... members of the Behavioral Ecology Research Group in Oxford ...
... plume of sulphur dioxide that spewed from Chile,s Puyehue-Cordn Caulle ... south of Santiago. After lying dormant for more than ... of this major volcanic eruption. On 4 June, a fissure ... over 10 km high. ,Several thousand people were evacuated as ...
... On rare occasion, the light-sensing photoreceptor cells in the eye ... captured photons, when in reality they haven,t. For years this ... of Science , neuroscientists at the Johns Hopkins University ... in photoreceptors can be triggered by heat, as well, giving ...
Cached Biology News:Clever tool use in parrots and crows 2Clever tool use in parrots and crows 3Clever tool use in parrots and crows 4Why animals don't have infrared vision 2Why animals don't have infrared vision 3
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
... has been developed specifically for the ... on microwell plates/strips. Coating Stabilizer ... the antibody or protein antigen portion ... Product is filtered at 0.2 microns., ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Biology Products: